JPMorgan Chase & Co. Increases Stake in Siga Technologies Inc. $SIGA

JPMorgan Chase & Co. lifted its stake in shares of Siga Technologies Inc. (NASDAQ:SIGA) by 744.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 211,055 shares of the company’s stock after acquiring an additional 186,067 shares during the period. JPMorgan Chase & Co. owned 0.29% of Siga Technologies worth $1,931,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the stock. Arrowstreet Capital Limited Partnership raised its holdings in Siga Technologies by 44.2% in the third quarter. Arrowstreet Capital Limited Partnership now owns 834,683 shares of the company’s stock valued at $7,637,000 after buying an additional 255,902 shares during the period. Bank of America Corp DE raised its holdings in Siga Technologies by 143.2% in the second quarter. Bank of America Corp DE now owns 405,730 shares of the company’s stock valued at $2,645,000 after buying an additional 238,869 shares during the period. CSM Advisors LLC raised its holdings in Siga Technologies by 66.5% in the third quarter. CSM Advisors LLC now owns 596,512 shares of the company’s stock valued at $5,458,000 after buying an additional 238,255 shares during the period. Millennium Management LLC raised its holdings in Siga Technologies by 353.8% in the third quarter. Millennium Management LLC now owns 256,337 shares of the company’s stock valued at $2,345,000 after buying an additional 199,852 shares during the period. Finally, Vanguard Group Inc. raised its holdings in Siga Technologies by 5.7% in the third quarter. Vanguard Group Inc. now owns 2,655,942 shares of the company’s stock valued at $24,302,000 after buying an additional 142,036 shares during the period. 55.40% of the stock is currently owned by hedge funds and other institutional investors.

Siga Technologies Stock Down 12.9%

SIGA opened at $4.53 on Wednesday. The firm has a market capitalization of $324.53 million, a P/E ratio of 14.61 and a beta of 1.05. The firm’s 50 day moving average is $5.99 and its 200-day moving average is $6.73. Siga Technologies Inc. has a 52-week low of $4.47 and a 52-week high of $9.62.

Siga Technologies (NASDAQ:SIGA) last posted its quarterly earnings data on Tuesday, March 10th. The company reported ($0.08) earnings per share (EPS) for the quarter. Siga Technologies had a net margin of 24.61% and a return on equity of 11.25%. The firm had revenue of $3.79 million for the quarter. Equities analysts expect that Siga Technologies Inc. will post 1.04 earnings per share for the current fiscal year.

Siga Technologies Announces Dividend

The business also recently declared a special dividend, which will be paid on Thursday, April 23rd. Stockholders of record on Tuesday, April 7th will be given a dividend of $0.60 per share. The ex-dividend date of this dividend is Tuesday, April 7th.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of Siga Technologies from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, March 12th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Siga Technologies Company Profile

Siga Technologies, Inc (NASDAQ: SIGA) is a specialty pharmaceutical company focused on the development, manufacturing and commercialization of medical countermeasures for public health emergencies and biological threats. The company’s flagship product, TPOXX® (tecovirimat), is the first and only antiviral approved by the U.S. Food and Drug Administration for the treatment of smallpox. Siga has entered into procurement and development contracts with U.S. government agencies, including the Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense, to supply TPOXX® for the Strategic National Stockpile.

Founded in 2002, Siga has built a pipeline of therapies targeting high-consequence pathogens such as smallpox, plague and other potential biothreat agents.